InvestorBrandNetwork (IBN) Content Platform

Nutriband (NASDAQ: NTRB), a pioneer in the science of using novel transdermal solutions and other innovative technologies, has announced that it has commenced trading on Upstream, a MERJ Exchange Market that is a fully regulated global stock exchange for digital securities and NFTs. The company, which began trading on Upstream today using the NTRB ticker symbol, is among the first issuers to dual list on the market. The company released a digital collectible NFT commemorating the dual listing, which is available for all Upstream participants to claim with a claim code: NTRB! “We are thrilled to be amongst the first companies to dual list on Upstream’s next generation marketplace,” said Nutriband CEO Gareth Sheridan in the press release. “We are adding new value to our shareholders while expanding our company and mission to a modern, global investor-base.”

To view the full press release, visit https://ibn.fm/9tMVN

About Nutriband Inc.

Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s lead product under development is an abuse deterrent fentanyl patch incorporating its AVERSA(TM) abuse deterrence technology. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion and accidental exposure of drugs with abuse potential. For more information about the company, please visit www.Nutriband.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has regained full compliance with NASDAQ minimum-bid price requirements. The company received a letter from the NASDAQ Stock Market LLC providing notification of the change in status; the letter was dated Jan. 4, 2023. According to the letter, the exchange determined that the closing bid price of the company’s common stock was at or above $1 per share for 10 consecutive business days, which is the minimum requirement. Therefore, ATNF has regained compliance.

To view the full press release, visit https://ibn.fm/P9tkR

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company driving groundbreaking studies into clinical programs that are seeking to address major unmet medical needs. The company’s focus is a novel program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). For more information about the company, visit www.180LifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at https://ibn.fm/ATNF 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, has entered into a definitive agreement. According to the announcement, the agreement is with a single institutional investor and is estimated to raise $8 million through a private placement offering with a single unit price $1.20. The offering defined each unit as one share of common stock (or a prefunded warrant to purchase one share of common stock) and one warrant exercisable for one share common stock at a price of $1.20 per share for a period of five years and 6 months from closing. The announced noted that no actual units will be issued in the offering. “After the placement agent fees and estimated offering expenses payable by the company, the company expects to receive net proceeds of approximately $7.5 million,” the announcement stated. “The offering is expected to close on Jan. 9, 2023, subject to customary closing conditions.”

To view the full press release, visit https://ibn.fm/4KDkx

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea (“OSA”) as well as snoring in adults. The Vivos Method represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for treating mild to moderate OSA. It has proven effective in the treatment of more than 31,000 patients worldwide by more than 1,650 trained dentists. The Vivos Method includes the Vivos Complete Airway Repositioning and/or Expansion (“CARE”) appliance therapy and associated protocols that alter the size, shape and position of the soft tissues that comprise a patient’s upper airway and palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild to moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentist training and other value-added services in connection with using the Vivos Method. For more information about this company, visit www.VivosLife.com.  

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Splash Beverage Group (NYSE American: SBEV), a portfolio company of leading beverage brands, today issued a letter to shareholders from Robert Nistico, SBEV’s CEO and chairman. “As we embark upon 2023, I wanted to take this opportunity to briefly update our shareholders on some key developments that have taken place at Splash Beverage Group since our last corporate update. Since our August update, we have continued to add distribution agreements and retail authorizations. This is a result of positive brand performance in existing accounts, and our growing reputation in the industry. Keep in mind that each new distributor and / or retail chain adds revenue for Splash,” Nistico stated in the letter, further detailing the company’s expansions and growth. “Each of our brands tap into unique trends in consumer preferences, and we believe that we are in the right categories at the right time. We are very grateful to have you as shareholders and we look forward to continuing to earn that confidence.”

To view the full press release, visit https://ibn.fm/ZIP8D

About Splash Beverage Group Inc.

Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wine by the glass, SALT flavored tequilas, Pulpoloco sangria, and TapouT performance hydration and recovery drink. Splash’s strategy is to rapidly develop early stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution. For more information about the company, visit www.SplashBeverageGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SBEV are available in the company’s newsroom at https://ibn.fm/SBEV

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced interim results for the first five patients dosed in its Phase II STOP (Study of the Treatment of Overeating utilizing Psilocybin) trial. In collaboration with the University of Florida, the trial is evaluating TRP-8802 (oral psilocybin) in patients with binge eating disorder (“BED”) and represents the first use of psilocybin in conjunction with psychotherapy as a therapeutic intervention in patients with BED. “The magnitude and consistency of the trends observed in this interim analysis are incredibly encouraging,” said Tryp’s CEO Jim Gilligan, Ph.D. “Furthermore, these preliminary results provide us with the confidence that BED is a viable target for future studies with psychedelic-assisted psychotherapy utilizing TRP-8803, our proprietary IV formulation of psilocin that alleviates numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. Our strategy is to perform small exploratory studies using TRP-8802 for unique indications including BED, fibromyalgia and irritable bowel syndrome, all in partnership with leading academic institutions. Once a positive clinical signal is identified in studies using TRP-8802, we intend to perform subsequent studies with TRP-8803.”

To view the full press release, visit https://ibn.fm/uKc7s

About Tryp Therapeutics Inc.

Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp’s lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) that alleviates numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The company has an ongoing phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida and an upcoming phase 2a clinical trial with the University of Michigan for the treatment of fibromyalgia, both of which are utilizing TRP-8802 (synthetic, oral psilocybin) to demonstrate efficacy in these indications. Where a preliminary clinical benefit has been demonstrated, subsequent studies are expected to utilize TRP-8803, which has the potential to further improve efficacy, safety and patient experience. For more information about the company, please visit www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

SideChannel (OTCQB: SDCH) was featured in a recent “Cyber for Hire – The Managed Security Podcast” published by SC Media. The piece delves into factors to consider when paring a company with a fractional or virtual CISO, looking at how to find a harmonious match. SideChannel’s founder and CEO Brian Haugli joined program co-hosts Bradley Barth and Ryan Morris to discuss the facets that go into the role or service to successfully make the solution work for a client long term. “I’ve been across the whole spectrum… Starting and building the company that I’m in, SideChannel, I started out as a solo practitioner. So, I’ve lived that life and figured that out, now scaling it to offer many different CISOs to many different clients,” Haugli said, discussing what he has learned, now seeing the whole gamut of how to make the connection work between personalities and backgrounds. “Geography is actually a big deal, and it’s mostly for the service provider/vCISO,” he said, discussing the need for providers to consider compatibility and adjustments required when working with a client on the east vs. west coast or their various location. “Expertise… that’s probably the largest component,” Haugli further explained, sharing insight on the key requirement for the CISO to serve the clients they are working with.

To view the full podcast, visit https://ibn.fm/vAbfs

About SideChannel Inc.

SideChannel is committed to creating top-tier cybersecurity programs for mid-market companies to help them protect their assets. SideChannel employs what it believes to be skilled and experienced talent to harden these companies’ defenses against cybercrime, in its many forms. SideChannel’s team of C-suite level information security officers possess a combined experience of over 400 years in the industry. To date, SideChannel has created more than 50 multilayered cybersecurity programs for its clients. For more information about the company, visit SideChannel.com.

NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has entered into an exclusive license agreement with the University of Pittsburgh. According to the announcement, the agreement gives Genprex a worldwide, exclusive license to a patent application along with related technology; the agreement also grants the company a worldwide, nonexclusive license to use certain related know-how. The agreement is related to gene therapy for type 2 diabetes using the genes of the Pdx1 and MafA transcription factors. The company believes that the technologies licensed from the university may have the potential to change the course of the disease and provide long-term efficacy for millions of individuals diagnosed with both type 1 and type 2 diabetes. “This marks the company’s third technology license this year supporting our diabetes program, demonstrating the continued strengthening of our intellectual property portfolio, our diabetes program and our position as a lead innovator in emerging diabetes gene therapies,” said Genprex president and CEO Rodney Varner in the press release. “We are thrilled to have secured multiple cutting-edge technologies from Pitt that expand our diabetes gene therapy program and specifically target type 1 and type 2 diabetes.”

To view the full press release, visit https://ibn.fm/qElyq

About Genprex Inc. 

Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, which currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its proprietary, nonviral ONCOPREX(R) Nanoparticle Delivery System, which the company believes is the first systemic, gene-therapy delivery platform used for cancer in humans. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is then administered intravenously, where it is then taken up by tumor cells that express proteins that are deficient in the body. The company’s lead product candidate, REQORSA (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for non-small cell lung cancer (“NSCLC”), with each of these clinical programs receiving a fast track designation from the Food and Drug Administration, as well as small cell lung cancer. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an endoscope and an adeno-associated virus (“AAV”) vector to deliver Pdx1 (“Pdx1”) and MafA (“MafA”) genes to the pancreas. In models of type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system. In a similar approach, GPX-003 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. For more information, please visit the company’s website at www.Genprex.com

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

• With over 500 million ransomware attacks in 1H2021, corporations have been increasingly looking for ways to safeguard their internal IT systems
• The need for data protection has been further heightened by increased regulatory scrutiny from foreign and domestic governmental agencies
• In the U.S., the recently passed Federal ADPPA privacy law will coincide with California’s Consumer Privacy Act, with the latter set to come into effect on January 1, 2023
• With a broad toolkit focused on data security and management, Data443 have sought to capitalize on the expanding global need for data protection services

Towards the beginning of May 2021, U.S. fuel prices started to unexpectedly spike. The Colonial Pipeline company, operator of a systemically crucial 5,500 mile long pipeline engaged in transporting fuel from the Gulf Coast to the New York metro area was shut down, suspending the flow of over 100 million gallons of fuel every day between Texas and New York (https://ibn.fm/YoGfq). In ensuing days, news would break that DarkSide, an emerging hacking consortium had held the company’s IT systems hostage – freezing its data and threatening to leak sensitive corporate information online. Colonial Pipeline would go on to pay a ransom of $2.3 million or 63.7 bitcoin at the time. Whilst dramatic in nature, the Colonial Pipeline ransomware attack was just one of nearly 500 million ransomware attacks taking place in the first half of 2021, a clear illustration of the need for corporations to engage in more robust cyber security efforts going forward.

Focusing in on data security and a privacy-forward methodology, Data443 Risk Mitigation (OTC: ATDS) has emerged as a key player within the cyber security arena, strategically positioned to benefit from increased demand for data protection with its portfolio of software solutions, allowing for a unified…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to ATDS are available in the company’s newsroom at https://ibn.fm/ATDS

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

CubCrafters, the leading designer and manufacturer of light-sport, experimental and Part 23 certified backcountry aircraft, has been modeled around a culture of innovation. This, coupled with the dedication and output of its now more than 200 highly skilled personnel, has propelled the company to be a leader in its market segment. “This status is evidenced by several parameters, including CubCrafters’ average aircraft revenue per customer, which has grown from just over $5 million in 2001 to over $30 million in 2021, according to the company’s Regulation A+ presentation. In fact, the company reported resilient sales as well as a growing market share in 2021 despite pandemic-related supply chain issues,” a recent article reads. “As a further testament to this leadership, two CubCrafters aircraft are the recipients of only a handful of Part 23 certificates that the FAA has issued over the last two decades. Moreover, CubCrafters has been among the very few companies to obtain a new type certificate – an approval that signifies compliance with requirements on airworthiness, design of the aircraft and all component parts, noise, exhaust emission standards, and more – in backcountry aviation since 1970. CubCrafters’ distinctiveness has led to demand for its aircraft, leading to the company being fully booked until 2024.”

To view the full article, visit https://ibn.fm/Sz2QU

About CubCrafters Inc.

Founded in 1980 by Jim Richmond, CubCrafters’ roots are in the 80+ year history of classic grassroots aviation, but the company’s products and services are innovative and completely modern. CubCrafters designs and manufactures experimental, LSA, and Part 23 certified aircraft. The Carbon Cub family of aircraft redefined expectations for the backcountry flying experience with innovative design, modern materials, powerful engines, and breathtaking performance. The company’s flagship XCub aircraft is offered in both nosewheel and tailwheel configurations, and substantially expands the mission profile of sport utility aircraft with higher speed, longer range and larger payload. The key to CubCrafters’ success is its ability to create unique value in the experience of personal adventure aviation. For more information about the company, visit www.CubCrafters.com.

NOTE TO INVESTORS: The latest news and updates relating to CubCrafters are available in the company’s newsroom at https://ibn.fm/CUB

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Foresight Autonomous Holdings (NASDAQ: FRSX) (TASE: FRSX), an innovator in automotive vision, and its wholly owned subsidiary Eye-Net Mobile Ltd., have announced a new collision-prediction solution. Called Eye-Zone(TM), the solution is a virtual sensor designed for the automotive industry. Eye-Zone will be on display at CES 2023, which will be held in Las Vegas on Jan. 5–8, 2023. CES visitors will be able to meet key members of the Eye-Zone team during the show as well as enjoy a behind-the-wheel experience on Eye-Net’s 3D driving simulator. According to the announcement, Eye-Zone is a vehicle-to-everything (“V2X”) collision-detection and accident-prevention solution designed to notify the driver through a unique virtual sensor that provides information about real-time location, movement characteristics and probability of collision with road users around the vehicle. The company noted that Eye-Zone can be integrated with various automotive systems, including Advanced Driver Assistance Systems, navigation systems and infotainment systems.

To view the full press release, visit https://ibn.fm/3Jt80

About Foresight Autonomous Holdings Ltd.

Foresight Autonomous Holdings is a technology company developing smart multispectral vision software solutions and cellular-based applications. Through the company’s wholly owned subsidiaries — Foresight Automotive Ltd., Foresight Changzhou Automotive Ltd. and Eye-Net Mobile Ltd. — Foresight develops both “in-line-of-sight” vision systems and “beyond-line-of-sight” accident-prevention solutions. Foresight’s vision solutions include modules of automatic calibration and dense three-dimensional (“3D”) point cloud that can be applied to different markets such as automotive, defense, autonomous vehicles and heavy industrial equipment. Eye-Net Mobile’s cellular-based solution suite provides real-time, precollision alerts to enhance road safety and situational awareness for all road users in the urban mobility environment by incorporating cutting-edge AI technology and advanced analytics. For more information, visit the company’s website at www.ForesightAuto.com.

NOTE TO INVESTORS: The latest news and updates relating to FRSX are available in the company’s newsroom at http://ibn.fm/FRSX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

IBN, a multifaceted financial news and publishing company for private and public entities, today announced the launch of Investor Relations Plus (+), its customized IR solution designed to support both issuers and IR professionals. IBN continually works to adapt to the evolving needs of its client partners, and with offerings such as press release enhancement through InvestorWire, gleans insight from traditional PR professionals and IR firms while strengthening its value proposition for both public and privately held companies operating across a wide spectrum of industries. “Many of the investor relations firms and professionals we’ve worked alongside over the past 17+ years have appreciated our team’s ability to help out in more areas than content creation and distribution,” said IBN’s Director of Client Solutions Christopher Johnson. “With the introduction of Investor Relations Plus (+), we have a new solution that can provide a full array of traditional investor relations services to help issuers and IR professionals wherever needed.”

To view the full press release, visit https://ibn.fm/tK66t

About IBN

IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (“DBP”), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Processa Pharmaceuticals (NASDAQ: PCSA), a diversified clinical-stage company developing products to improve survival and/or the quality of life for patients with unmet medical need conditions, today announced that its CEO Dr. David Young will present an update on Processa’s future therapeutic focus and strategy at the upcoming Biotech Showcase. The presentation is scheduled to begin at 10 a.m. PT on Jan. 11, 2023. Interested parties should visit https://ibn.fm/LcSFO to register for and access the webcast. In addition, the company’s management will be available for one-on-one meetings with potential investors and partners in San Francisco throughout the J.P. Morgan 41st Annual HealthCare Conference week. Meetings can be requested through the Biotech Showcase partnering platform or by contacting Processa directly at [email protected].

To view the full press release, visit https://ibn.fm/Z92Fb

About Processa Pharmaceuticals Inc.

The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The company uses its Regulatory Science Approach criteria when selecting and developing drugs to achieve high-value milestones effectively and efficiently. Current clinical pipeline programs include: Next Generation Capecitabine PCS6422 (metastatic colorectal cancer, breast cancer), PCS3117 (pancreatic and other cancers), PCS11T (small cell lung and other cancers), PCS12852 (gastroparesis, functional constipation), and PCS499 (ulcerative necrobiosis lipoidica). Members of the Processa development team have been involved with more than 30 approvals for indications in almost every division of the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults, has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for its own daytime-nighttime appliance (“DNA”). According to the announcement, the clearance for the DNA appliance as a Class II device “gives rise to a completely new treatment regimen for mild-to-moderate OSA.” Vivos noted that the device is the company’s longest standing appliance and sees the widest use among Vivos-trained dentists. “This clearance is the culmination of years of pioneering clinical work,” said Vivos Therapeutics chair and CEO Kirk Huntsman in the press release. “For the first time, the FDA has formally recognized the benefits of our proprietary core technology in our DNA appliance (without mandibular advancement) as an effective treatment for mild-to-moderate OSA in adults. The FDA now joins other international regulatory bodies in recognizing the efficacy of our patented technology in the reduction and resolution of many of the symptoms of OSA that result from a lack of development of the jaws and oral cavity. We believe the DNA treatment can be life changing for many OSA patients, and we look forward to continued market adoption of our expanded menu of treatments for this debilitating condition.”

To view the full press release, visit https://ibn.fm/Cs0RT

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea (“OSA”) as well as snoring in adults. The Vivos Method represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution. It has proven effective in the treatment of more than 31,000 patients worldwide by more than 1,650 trained dentists. The Vivos Method includes the Vivos Complete Airway Repositioning and/or Expansion (“CARE”) appliance therapy and associated protocols that alter the size, shape and position of the soft tissues that comprise a patient’s upper airway and palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild to moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentist training and other value-added services in connection with using the Vivos Method. For more information about this company, visit www.VivosLife.com.  

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that research evaluating the company’s gene therapy for type 1 diabetes will be presented at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (“ATTD”). The preclinical data will be presented by GNPX research collaborators at the University of Pittsburg. The conference will be held in Germany on Feb. 22 through 25, 2023. The presentation, which is titled “Pancreatic Intraductal Infusion of Adeno-Associated Virus to Treat Non-Human Primates in a Toxin-Induced Diabetes Model,” will be delivered by Ranjeet Kalsi, DO, who will be representing the laboratory of Dr. George Gittes, MD, a professor of surgery and pediatrics and chief of the Division of Pediatric Surgery at the University of Pittsburgh School of Medicine. The presentation is scheduled for Feb. 25 at 1:45 p.m. Central European Standard Time.

To view the presentation, visit https://ibn.fm/EIf2y

To view the full press release, visit https://ibn.fm/x2zZN

About Genprex Inc. 

Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, which currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its proprietary, nonviral ONCOPREX(R) Nanoparticle Delivery System, which the company believes is the first systemic, gene-therapy delivery platform used for cancer in humans. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is then administered intravenously, where it is then taken up by tumor cells that express proteins that are deficient. The company’s lead product candidate, REQORSA (quaratusugene ozeplasmid), is being evaluated as a treatment for both non-small cell lung cancer (“NSCLC”), with each of its clinical programs receiving a fast track designation from the Food and Drug Administration, and small cell lung cancer. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an endoscope and an adeno-associated virus (“AAV”) vector to deliver Pdx1 (“Pdx1”) and MafA (“MafA”) genes to the pancreas. In models of type 1 diabetes, the genes express proteins that transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system. In type 2 diabetes, where autoimmunity is not at play, it is believed that exhausted beta cells are also rejuvenated and replenished. For more information, please visit the company’s website at www.Genprex.com

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

180 Life Sciences (NASDAQ: ATNF) today announced the publication of a review entitled “Dupuytren’s disease: a localized and accessible human fibrotic disorder” in the journal Trends in Molecular Medicine. In the article, the authors at the University of Oxford, led by Professor Jagdeep Nanchahal, chairman of the medical advisory board of 180 Life Sciences, describe the biology of Dupuytren’s disease, to which their important contributions are recognized by the International Dupuytren Award in 2019, 2020 and 2021. “This review provides an important update on our understanding of molecular basis of Dupuytren’s disease,” said Professor Marc Feldmann FRS, co-chairman of 180 Life Sciences. “By unravelling the signaling pathways and demonstrating their link to the genetics, Professor Nanchahal and his colleagues identified tumor necrosis factor (‘TNF’) as a therapeutic target in the laboratory and went on to demonstrate the efficacy of anti-TNF for the treatment of early-stage Dupuytren’s disease in a phase 2b clinical trial, the results which have been previously announced. Importantly, they have recently shown that anti-TNF treatment could also be cost-effective.”

To view the full press release, visit https://ibn.fm/zE5pu

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company driving groundbreaking studies into clinical programs, which are seeking to address major unmet medical needs. The company’s focus is a novel program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor).

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at http://ibn.fm/ATNF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

SideChannel’s (OTCQB: SDCH) CEO and Founder Brian Haugli was featured in a recent podcast produced by Hacker Valley Studio. The discussion centers around strategy and leadership in cybersecurity, with Haugli sharing what he has learned about a purposeful approach. “Strategy is not technology, it’s figuring out what you want to look like when you grow up, in a sense,” Haugli said, discussing his philosophy and the tenants in creating a strong security strategy. “Everyone jumps to the shiny object. What can I buy to go solve this problem? You never stop and question: Was that the first problem I was supposed to solve? … I think a lot of people throw strategy around as a grander concept and don’t actually think about the elements that need to go into building one. You need to align to a definition that supports your business and outcomes, and that’s what is strategic.”

To view the full article, visit https://ibn.fm/THPDg

About SideChannel Inc.

SideChannel is committed to creating top-tier cybersecurity programs for mid-market companies to help them protect their assets. SideChannel employs what it believes to be skilled and experienced talent to harden these companies’ defenses against cybercrime, in its many forms. SideChannel’s team of C-suite level information security officers possess a combined experience of over 400 years in the industry. To date, SideChannel has created more than 50 multilayered cybersecurity programs for its clients. For more information about the company, visit SideChannel.com.

NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

• Companies that experience data breaches face, on average, $4.35 million in consequential costs, demonstrating the importance of an effective cybersecurity response
• Small to medium-sized businesses (“SMBs”) generally find the costs of hiring full-time cybersecurity experts to be prohibitive, making it difficult for them to effectively protect themselves from potential cyber crimes
• Virtual chief information security officer (“vCISO”) services are filling the breach with expert cybersecurity consultancy provided on a contract basis that is far more affordable than a full-time hire
• Cybersecurity services and technology provider SideChannel Inc. provides vCISO consultancy as well as proprietary Enclave software that addresses access control needs through microsegmentation
• SideChannel recently reported that its solutions have resulted in 71 percent YOY revenue growth with vCISO-specific services rising 93 percent and recurring software & services growing 367 percent

The industry providing virtual chief information security officer (“vCISO”) services is positioned to grow, given that cybercrime is one of the fastest-growing crimes in the United States and that the average cost of a data breach is $4.35 million, but the cost of hiring a full-time staff CISO can itself run into the hundreds of thousands of dollars, a recent Forbes report notes (https://ibn.fm/1qTwi).

Virtual CISOs provide high-level security service as a consultancy contract without the need for committed staffing, offering a more affordable option. Cybersecurity services and technology provider SideChannel (OTCQB: SDCH) is demonstrating the popularity of vCISO solutions for…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

DoubleDown Interactive (NASDAQ: DDI), a leading gaming company delivering unique player experiences across a variety of genres, today announced its participation in the 25th annual Needham Growth Conference. The event is slated to take place from Jan. 10 – 12, 2023, at The Lotte New York Palace in New York City. The company is scheduled to present at 4:30 p.m. ET on Jan. 10, and its management will host one-on-one meetings with investors throughout the conference. Interested parties should visit https://ibn.fm/Qqr0W to register for and access the presentation. In addition, a replay will be available in the Investor Relations section of DoubleDown’s website.

To view the full press release, visit https://ibn.fm/y1jhz

About DoubleDown Interactive Co. Ltd.

DoubleDown Interactive is a leading developer and publisher of digital games on mobile and web-based platforms. The company is the creator of multi-format interactive entertainment experiences for casual players, bringing authentic Vegas entertainment to players around the world through an online social casino experience. Its flagship title, DoubleDown Casino, has been a fan-favorite game on leading social and mobile platforms for years, entertaining millions of players worldwide with a lineup of classic and modern games. For more information, visit www.DoubleDownInteractive.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

SideChannel’s (OTCQB: SDCH) CEO and Founder Brian Haugli was featured in a recent video interview published by NBC News. The piece discusses an alert issued by the FBI and Homeland Security over cyber attacks targeting the data of teachers, staff and even students as schools come back in session. NBC News’ Tom Winter speaks with stakeholders and experts in the fight against cyber crime as nationwide concerns grow after Los Angeles has seen a trend of these attacks. “These organizations have payroll; they have HR. When I was in the Department of Defense, we used to track some of these groups when they went on holiday and vacations. So, they operate very much like a business,” Haugli said of the threat and the challenge for parents when a child’s digital identity has been stolen. “My kid will inherit this problem and now have to figure this out in ten years. They might go for their first car loan or apply for financial aid and now, suddenly, have all this credit debt…”

To view the full article, visit https://ibn.fm/1sYyL

About SideChannel Inc.

SideChannel is committed to creating top-tier cybersecurity programs for mid-market companies to help them protect their assets. SideChannel employs what it believes to be skilled and experienced talent to harden these companies’ defenses against cybercrime, in its many forms. SideChannel’s team of C-suite level information security officers possess a combined experience of over 400 years in the industry. To date, SideChannel has created more than 50 multilayered cybersecurity programs for its clients. For more information about the company, visit SideChannel.com.

NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

PetVivo Holdings (NASDAQ: PETV, PETVW), an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals, recently announced that it has begun the application process to dual list its shares on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex and MERJ Exchange Limited. According to the announcement, the planned dual listing is designed to provide the company with access to a global, digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal and USD, unlocking liquidity and enhancing price discovery while globalizing the opportunity to invest in NASDAQ-listed PetVivo. “We are always looking for ways to provide greater liquidity and value to our shareholders,” said PetVivo CEO John Lai. “We see a dual listing on Upstream as being an excellent way to reach a worldwide market of potential new investors who can learn about our company.”

To view the full press release, visit https://ibn.fm/CJ8eS

About PetVivo Holdings Inc.

PetVivo Holdings is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The company’s strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics. PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of nineteen patents protects the company’s biomaterials, products, production processes and methods of use. The company’s lead product SPRYNG(TM) with OsteoCushion(TM) technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in dogs and horses, is currently available for commercial sale. For more information about PetVivo and its revolutionary product, please contact [email protected] or visit www.PetVivo.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

SPYR (OTCQB: SPYR) CEO Tim Matula has released comments regarding the company, which is a diversified technology company developing products leveraging the Internet of Things (IoT) for consumer use and large-scale applications and industries. Matula commented on noteworthy events during 2022 as well as the company’s outlook for 2023. After thanking shareholders, Matula noted that 2022 was “eventful” for SPRY, including the introduction of new management at the beginning of the year as the company evaluated its business and began looking for potential merger acquisitions. That process culminated in June when the company purchased the assets of GeoTraq in a transaction that included the patent and the inventory of more than 13,000 chip sets; SPYR also entered a manufacturing agreement to build the chip sets into finished goods inventory. GeoTraq is a mobile IoT module manufacturer and connectivity provider that offers asset tracking and remote monitoring through mobile IoT modules with global connectivity. “In July we decided began the process of evaluating the performance of our Applied Magix subsidiary,” said SPRY CEO Tim Matula in the press release. “Based on that review, the board of directors concluded that we should focus on our GeoTraq purchase as the market for their products is growing and our belief that with proper funding we would be able to sell the asset tracking devises to a wide range of enterprise customers. On Dec. 12, 2022, we entered into a settlement agreement and release with shareholders resulting in the cancelation and return to treasury of 36,272,684 common shares, representing 10.48% of the issued and outstanding shares of the company as of Dec. 21, 2022. On Dec. 20, 2022, we wound down and dissolved Applied Magix in Nevada, and now we are 100% focused on growing our GeoTraq business, products and services. Our first goal is to complete the over 13,000 chip sets that are ready for assembly. In addition, as we receive further funding our focus will be on expanding our current engineering staff and migrating to 5G chip sets when we order additional chips. We look forward to the new year with enthusiasm as we concentrate all of our efforts on GeoTraq.”

To view the full press release, visit https://ibn.fm/1jt1o

About SPYR Inc.

SPYR Technologies is a technology company focused on the Internet of Things (“IoT”). Through its subsidiary GeoTraq business, SPYR develops and manufactures fully self-contained, ultra-small mobile IoT modules, including Trackertracker-M modules, for asset tracking and location-based services, and Sensorsensor-M modules, used for remote monitoring. SPYR continues to identify and target acquisitions that will grow its footprint in the industry and expand the products it offers consumers, including companies developing artificial intelligence (“AI”) and smart-technology products. For more information about this company, visit https://ir.spyr.com.

NOTE TO INVESTORS: The latest news and updates relating to SPYR are available in the company’s newsroom at https://ibn.fm/SPYR

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Foresight Autonomous Holdings (NASDAQ: FRSX) (TASE: FRSX), an innovator in automotive vision systems, today announced that it will showcase a live demonstration of its Mono2Stereo(TM) software-based solution at CES 2023. According to the update, the solution is designed to create 3D perception stereo vision from existing cameras to enhance the performance of existing mono-camera based advanced driver assistance systems (“ADAS”). “The year 2022 saw significant strategic developments for Foresight, as several vehicle manufacturers and tier one automotive suppliers engaged in proof of concept (‘POC’) projects to evaluate the company’s 3D stereoscopic solutions to enhance their existing ADAS systems,” said Haim Siboni, chief executive officer at Foresight. “CES 2023 will give us a chance to showcase our unique technological advances, demonstrating how our software-based solution can benefit the automotive industry.”

To view the full press release, visit https://ibn.fm/jF6R9

About Foresight Autonomous Holdings Ltd.

Foresight is a technology company developing smart multi-spectral vision software solutions and cellular-based applications. Through the company’s wholly owned subsidiaries, Foresight Automotive Ltd., Foresight Changzhou Automotive Ltd. and Eye-Net Mobile Ltd., Foresight develops both “in-line-of-sight” vision systems and “beyond-line-of-sight” accident-prevention solutions. Foresight’s vision solutions include modules of automatic calibration and dense three-dimensional (“3D”) point cloud that can be applied to different markets such as automotive, defense, autonomous vehicles and heavy industrial equipment. Eye-Net Mobile’s cellular-based solution suite provides real-time pre-collision alerts to enhance road safety and situational awareness for all road users in the urban mobility environment by incorporating cutting-edge AI technology and advanced analytics. For more information about Foresight and its wholly owned subsidiary, Foresight Automotive, visit www.ForesightAuto.com.

NOTE TO INVESTORS: The latest news and updates relating to FRSX are available in the company’s newsroom at http://ibn.fm/FRSX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

DarioHealth (NASDAQ: DRIO), a leader in the global digital therapeutics (“DTx”) market, today announced that a large Northeast U.S. supermarket chain selected Dario to help improve the cardiometabolic health of its employees beginning in the first quarter of 2023. This marks 100 enterprise contracts signed for DarioHealth and validates its strategic position as a leading provider of integrated digital chronic condition management solutions in the employer and payer markets. “Throughout 2022 we saw that the demand for our integrated multi-condition solutions grow at a steady pace, and the addition of this employer marks a tremendous achievement for Dario. Hitting our goal of 100 contracts by the end of 2022 is a testament to the vision we set forth over a year ago,” said Rick Anderson, president of Dario. “The fact that most of the contracts signed in 2022 and more than 50% of our pipeline are for multiple conditions represents market validation of our multi-condition suite approach. There is a clear trend with enterprise customers seeking multiple conditions from less vendors. Given our multi-condition suite strategy we believe that we are well positioned for growth in the future market.”

To view the full press release, visit https://ibn.fm/LL1wd

About DarioHealth Corp.

DarioHealth is a leading digital therapeutics (“DTx”) company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition platform. Dario’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company’s user-centric platform offers people continuous and customized care for health, disrupting the traditional episodic approach to health care. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results. Making the right thing to do the easy thing to do. Dario provides its highly user rated solutions globally to health plans and other payors, self-insured employers, providers of care and directly to consumers. To learn more about DarioHealth and its digital health solutions, or for more information, visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs. The company today announced its entry into a letter of intent with Massachusetts General Hospital (“MGH”), the largest teaching hospital of Harvard Medical School, to fund and conduct a phase 2a clinical trial investigating the effects of psilocybin-assisted psychotherapy in the treatment of patients aged 21+ suffering from irritable bowel syndrome (“IBS”). “MGH is an ideal partner for Tryp to expand on its strategy of utilizing TRP-8802 (oral psilocybin) to explore the clinical potential of psilocybin-assisted psychotherapy in new indications,” said Jim Gilligan, PhD, chief executive officer of Tryp Therapeutics. “With positive results in this study, Tryp would look to continue clinical development in IBS with TRP-8803, our proprietary formulation of IV-infused psilocin, that alleviates numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. Our ultimate goal is providing even more favorable outcomes and relief to the millions of patients currently suffering from IBS and its associated disorders. With this agreement in place, we will be in a position to submit the relevant IND.”

To view the full press release, visit https://ibn.fm/7cfby

About Tryp Therapeutics Inc.

Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp’s lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) that alleviates numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The company has an ongoing phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida and an upcoming phase 2a clinical trial with the University of Michigan for the treatment of fibromyalgia, both of which are utilizing TRP-8802 (synthetic, oral psilocybin) to demonstrate efficacy in these indications. Where a preliminary clinical benefit has been demonstrated, subsequent studies are expected to utilize TRP-8803, which has the potential to further improve efficacy, safety and patient experience. For more information about the company, please visit www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

BlockQuarry (OTC: BLQC), a Texas-based company with commercial-stage operations in cryptocurrency mine hosting and self-mining in the southeast United States, is reporting on its unaudited financial highlights for the three and nine months ended Sept. 30, 2022. Financial highlights of the report show total revenues for the three-month period s of $2.098 million with total revenue for the nine-month period of $4.46 million. The company’s total assets were $10.42 million with current liabilities of $16.4 million. Operational highlights for the period include partnering with a consultant to provide services to support the company’s efforts to uplist to a higher exchange as well as an agreement with Bitmain to amend an existing service framework agreement to increase hosting service fees from $0.05275 per kilowatt hour to $0.07 per kilowatt hour. In addition, the company announced that a board of directors charter has been submitted to the state of Nevada and that it has filed an amended S1 registration statement with the updated Q3 financial reports. The company also significantly reduced its convertible debt with legacy note holders. “I am extremely proud of our third-quarter financial performance, despite very difficult current overall market and cryptocurrency market conditions,” said BlockQuarry president and chair Alonzo Pierce in the press release. “We were able to book a phenomenal quarter that featured continued strong topline growth, and we made substantial headway on key corporate objectives. . . . We were successful in hitting a number of key objectives in Q3, including a necessary reworking of our agreement with Bitmain to protect the company and ensure we are covered during peak power months. We were also able to get our board of directors and advisors finalized as well as hire a consulting firm to help us with the uplisting process.”

To view the full press release, visit https://ibn.fm/CMx2Z

About BlockQuarry Corp.

BlockQuarry focuses on cryptocurrency mine hosting and self-mining operations at a leased property located in Gaffney, South Carolina. BlockQuarry also maintains a fleet of digital/cryptocurrency mining equipment and infrastructure. For more information about the company, visit www.BlockQuarry.io.

NOTE TO INVESTORS: The latest news and updates relating to BLQC are available in the company’s newsroom at http://ibn.fm/BLQC

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Sustainable Green Team (OTC: SGTM), an industry-leading wholesale manufacturer and supplier of consumer and industrial wood-based mulch, soil, and lumber products nationwide, announced that CEO Anthony J. Raynor was slated to present at the Global Unity Foundation’s Summit pitch competition; the competition was held Dec. 31, 2022. During his presentation, Mr. Raynor provided an overview of the company’s achievements and highlights for the past year; the presentation also included a review of SGTM’s upcoming opportunities and goals as well as the company’s vision for growth. According to the announcement, the mission of Global Unity Foundation (“GUF”) is to unite the world through humanitarian efforts by working with community leaders, influential individuals and socially conscience organizations to eradicate poverty, advance health and wellness, create economic sustainability and promote universal quality education. “I am excited to share our vision, passion, and plan to positively change our world at the Global Unity Summit and Gala,” said Sustainable Green Team CEO Anthony J. Raynor in the press release. “I believe that there is no greater way to end 2022 than presenting and networking in such a prestigious event as we enter the new year.”

To view the full press release, visit https://ibn.fm/pxs1C

About Sustainable Green Team Ltd.

The Sustainable Green Team is a wholesale manufacturer and supplier of wood-based mulch, soil and lumber products, selling directly to mass merchandisers, home centers, hardware stores, nurseries, garden centers, convenience stores and food stores, in addition to wholesalers and distributors. The company also provides arbor care and storm-recovery services at the residential, commercial and municipal levels while offering green-waste solutions to large- and small-scale waste disposal and recycling companies located throughout the southeastern United States. The company’s subsidiary, Mulch Manufacturing Inc., is the largest provider of cypress mulch in the country. SGTM has entered into an agreement with Australia-based VRM Biologik Group to bring VRM’s world-leading, soil-moisture technology to the Unites States at scale. HumiSoil(R) and XLR8 Bio(R) are soil-treatment products that rebuild soil hydration on a cellular level, improving the soil and the vegetation and agricultural products it supports. The company will make HumiSoil and XLR8 Bio available for home gardens and lawns throughout the United States to help relieve water use in cities as well as to help VRM Biologik Group in its mission to restore productivity in depleted topsoil in 25% of the world’s arable land. For more information about the company, please visit www.TheSustainableGreenTeam.com.

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, is reporting positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents. According to the announcement, SPU-21 is effective in controlling arthritis progression and exhibits positive data in arthritis suppression. The company noted that it is following a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (“RA”). The study is designed to evaluate the disease-suppressive effects of an SPU-21 peptide-guided anti-arthritis drug compared to the drug alone. SILO is working with the University of Maryland, Baltimore to develop the SPU-21 liposomal joint homing peptides. “We believe that the positive results of these latest tests show that our peptide with DEX given subcutaneously was effective in controlling arthritis progression,” said Silo Pharma CEO Eric Weisblum in the press release. “The effect of lipo-DEX was superior to that of DEX alone when both were administered via the SC route. Since patients widely prefer SC administration over intravenous (‘IV’) infusion for multiple reasons, we believe the superiority and practicality of our liposomal joint homing peptide bode well for broad market potential. Meanwhile, we continue to explore other novel therapeutics for optimal pairing with SPU-21, targeting rheumatoid arthritis as our initial indication.”

To view the full press release, visit https://ibn.fm/X9YF3

About Silo Pharma Inc.

Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research indications such as Alzheimer’s disease, PTSD and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research that the company believes will be transformative to the well-being of patients and the health-care industry. For more information about the company, visit www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

• CubCrafters recently announced that the US Department of Agriculture Wildlife Service had selected its flagship FAA-certified CC19 XCub for a new government aircraft-fleet-modernization contract
• The contract extends a long-term working relationship that has seen CubCrafters supply aircraft to various federal agencies since 2003
• CubCrafters aircraft have a lower operational cost than helicopters in addition to being reliable and safe with much of the same capability
• According to CubCrafters, the aircraft fleet modernization contract is important not only to the company as a supplier but also to investors participating in its ongoing public offering, which was recently qualified by the SEC

For close to two decades now, CubCrafters, a Yakima, Washington-based designer and manufacturer of Part 23 Certified, Experimental, and Light-Sport backcountry aircraft, has supplied aircraft to various US Federal Government agencies, including the US Air Force Research Laboratory, the US Air Force Flight Academy, the US Department of Agriculture (“USDA”), the US Department of Homeland Security (“DHS”), and the US Department of the Interior (“DOI”).

“Our long relationship with the US Government is a strong testament to our ability to design and manufacture exceptionally rugged utility aircraft for backcountry missions,” says CubCrafters President and CEO Patrick Horgan of the relationship that began in…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to CubCrafters Inc. are available in the company’s newsroom at https://ibn.fm/CUB

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Blue Hat Interactive (NASDAQ: BHAT), a leading communication services and internet data center (“IDC”) business provider, producer and developer, as well as an operator of mobile games and augmented reality (“AR”) education curricula and products in China, is reporting unaudited financial results. The results are for the second quarter 2022, or the three months ended June 30, 2022, and the first half of 2022, or the six months ended June 30, 2022. Highlights of the report include Q2 2022 total revenues of $1.7 million, gross profit of $1 million, loss from operations of $3.3 million and net loss from continuing operations of $3.4 million. First half 2022 numbers reached total revenues of $2 million, gross profit of $1.2 million, loss from operations of $6 million and net loss from continuing operations of $6.2 million. The company also reported $3 million in cash and cash equivalents as of June 30, 2022. The report noted that the global COVID-19 pandemic has negatively impacted the company’s financial performance. “In order to cope with the current situation of the economy environment, some adjustments have been made to the company’s business, and the company has suspended or reduced the AR Immersive Course (“ARIC”), game and communication business, which were severely affected by the COVID-19 pandemic,” said Blue Hat Interactive CEO Xiaodong Chen in the press release. “The company has increased the commodity supply chain commodity trading platform project and increased the breadth of the company’s business. At the same time, the company has increased the investment and development of some new projects such as new energy graphene, which will provide some foundation for the future development of the company, to grow the company steadily and maximize shareholder value.”

To view the full press release, visit https://ibn.fm/wVll2

About Blue Hat Interactive Entertainment Technology

Blue Hat is a leading communication services and IDC business provider as well as a producer, developer and operator of AR interactive entertainment games, toys and educational materials in China. Distinguished by its own proprietary technology, Blue Hat aims to create an engaging, interactive and immersive community for its users.

NOTE TO INVESTORS: The latest news and updates relating to BHAT are available in the company’s newsroom at http://ibn.fm/BHAT

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF), the digital face of the plant-based community operating a one-stop shop for plant-based products, has filed its interim financial statements for the six-month period ended Sept. 30, 2022. The company has also filed associated management’s discussion along with analysis and related officer certifications for the same period. Highlights of the report include gross revenue for the company totaling $8,869,579 and cost of goods sold reaching $5,542,113. Net loss for the six-month period was $8,964,219. The company also stated that, as it has filed the interim filings, together with the filing of its audited annual financial statements for the year ended March 31, 2022, as well as associated management discussion and analysis and related officer certifications, it anticipates applying to the British Columbia Securities Commission for full revocation of the “failure to file” cease trade order (“CTO”) issued by the commission in October 2022. “Trading is expected to resume on the Canadian Securities Exchange shortly after the revocation of the CTO,” the company said in the announcement. “The company is now current with all regulatory financial statement filings.”

To view the full press release, visit https://ibn.fm/zexPo

About PlantX Life Inc.

As the digital face of the plant-based community, PlantX is the one-stop shop for everything plant based. With its fast-growing category verticals, the company offers customers across North America more than 5,000 plant-based products. In addition to offering meal and indoor-plant deliveries, the company currently has plans to expand its product lines to include cosmetics, clothing and its own water brand. However, the business is not limited to an e-commerce platform. PlantX uses its digital platform to build a community of like-minded consumers and, most importantly, to provide education. Its successful enterprise is being built and fortified on partnerships with the top nutritionists, chefs and brands. The company eliminates the barriers to entry for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier and happier life. For more information about this company, please visit www.PlantX.com and www.PlantX.ca.

NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has recently filed national applications at the U.S. Patent and Trademark Office designed to provide additional patent protection for its lead product candidate, PH94B. The company has also filed similar applications with counterpart patent authorities in major pharmaceutical markets outside the United States. The filings are related to PH94B and the treatment of adjustment disorder (“AjD”). According to the company, these filings are a strategic “next step” in VistaGen’s ongoing efforts to enhance potential commercial protection across its CNS pipeline in key pharmaceutical marketsand provide global exclusivity platform for PH94B in AjD; the company is working to provide patent protection that is similar to that of its protection for PH94B for the treatment of social anxiety disorder (“SAD”) as well as its exclusive late-clinical stage product candidate, PH10, for the treatment of major depressive disorder (“MDD”). The company also noted that it is in the process of finalizing an acquisition of its acquisition of Pherin Pharmaceuticals Inc., which will include Pherin’s entire pherine pipeline as well as intellectual property rights to PH94B, a substance that is in phase 3 development for the treatment of SAD and phase 2 development for the treatment of AjD with anxiety (“AjDA”), and PH10, which is in clinical development for MDD. The acquisition will also give VistaGen full ownership of three new early clinical-stage pherine product candidates: PH15 for cognition improvement, PH284 for appetite-related disorders, and PH80 for migraine and hot flashes.

To view the full press release, visit https://ibn.fm/OVJEk

About VistaGen Therapeutics Inc.

VistaGen is a late clinical-stage CNS-focused biopharmaceutical aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The company is advancing therapeutics with the potential to be faster acting and with fewer side effects and safety concerns than those that are currently available. VistaGen’s clinical-stage candidates are targeting multiple types of anxiety and depression. PH94B and PH10 belong to a new class of drugs known as pherines, which are odorless and tasteless investigational neuroactive steroids designed with a novel rapid-onset mechanism of action that activates chemosensory neurons in the nasal passages and can impact the olfactory-amygdala neural circuits without systemic uptake or direct activity on CNS neurons in the brain. VistaGen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression — one mind at a time. For more information about the company, please visit www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has released a letter to shareholders; the letter is signed by CEO James Woody. In the letter, Woody notes that the company’s priority continues to be its clinical programs, repurposing anti-tumor necrosis factor (“TNF”) drugs for the treatment of Dupuytren’s disease, frozen shoulder and post-operative delirium. Woody reports that results from the company’s phase 2B trial exceeded expectations and showed that the treatment will most likely be cost effective. In the letter, Woody stated that, after obtaining scientific advice from the UK Medicines and Healthcare products Regulatory Agency (“MHRA”) and after discussions with regulatory consultants in the United States and United Kingdom, the company is preparing the material required to seek marketing authorization in the UK; the company plans on filing the application in mid-2023. “Enrollment to the trial of anti-TNF for early-stage frozen shoulder is slower than anticipated in the UK as patients typically present to physical therapists and the processes are subject to delays,” stated 180 Life Sciences CEO James Woody in the shareholder letter. “In the USA, all such patients are seen by orthopedic physicians, who are relatively easy to access. The trial team has implemented several strategies to improve recruitment, and we hope that these will be effective. Preparation for the trial of anti-TNF to prevent the development of postoperative delirium remains on track, and we anticipate that the first patient will be recruited in the first half of 2023. Our focus remains on our clinical portfolio. . . and we plan to continue to evaluate the timing and cost/benefit of additional ongoing research for our early discovery programs.”

To view the full shareholder letter, visit https://ibn.fm/ZkCj1

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease: inflammation. The company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The company’s primary platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor). For more information about the company, visit www.180LifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at https://ibn.fm/ATNF 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

SideChannel Inc. (OTCQB: SDCH) CEO Brian Haugli was one of several cybersecurity experts quoted in a recent PEW article reporting on the fact that at least 18 state governors have banned the use of the social media app TikTok on government devices. The article, titled “Governors’ TikTok Bans Make Sense, Cybersecurity Experts Say,” note that the state leaders are concerned about potential security risks because the app is owned by a Chinese company and may be used to collect data from users’ devices. The article contains quotes from numerous cybersecurity experts in support of the action, which could be viewed as political; all the states making the decision were led by Republican governors. Some governors took further action, banning other Chinese-owned apps and products such as WeChat, QQWallet and AliPay. Haugli was also quoted in an online article published by The Information titled “TikTok Owner Now Aiming to Expand into U.S. Enterprise Software Market.” In addition, the PEW article noted that bipartisan action had been taken on the federal level, with the U.S. Senate unanimously passing a bill that would prohibit federal employees from using TikTok on government-owned devices. “TikTok can access your camera and phone, the Wi-Fi connection, contacts, GPS, storage. It can read what you are doing and the things you’ve done,” said SideChannel CEO Brian Haugli in the article. “That thing can tell you where your eyeballs are looking.”

To view the full articles, visit https://ibn.fm/DAw0r and https://ibn.fm/gtFUC

About SideChannel Inc.

SideChannel is committed to creating top-tier cybersecurity programs for mid-market companies to help them protect their assets. SideChannel employs what it believes to be skilled and experienced talent to harden these companies’ defenses against cybercrime, in its many forms. SideChannel’s team of C-suite level information security officers possess a combined experience of more than 400 years in the industry. To date, SideChannel has created more than 50 multilayered cybersecurity programs for its clients. For more information about the company, please visit www.SideChannel.com. 

NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Standard Lithium (TSX.V: SLI) (NYSE American: SLI) (FRA: S5L), a leading near-commercial lithium company, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for Standard Lithium’s third U.S. patent application. The application, serial no. 16/895,783, titled “Process for Recovering Lithium from Brines,” is in addition to Standard Lithium’s other two U.S. patent applications for which Notices of Allowance have been earlier issued by the USPTO. The three applications comprise a portion of Standard Lithium’s novel and proprietary technique for continuous Direct Lithium Extraction (“DLE”) from lithium brines. “We are pleased to have received the Notice of Allowance for the final U.S. patent application of the company’s lithium extraction technology,” said Dr. Andy Robinson, Standard Lithium’s president and COO. “We will continue to strengthen our IP portfolio, but, more importantly, we are actively advancing our south Arkansas lithium projects and doing so by applying sustainable, scalable and fully-integrated modern processing technologies to unlock new U.S. commercial lithium production.”

To view the full press release, visit https://ibn.fm/zQWn9

About Standard Lithium Ltd.

Standard Lithium is a leading near-commercial lithium development company with a portfolio of projects in process. The company’s flagship projects, the LANXESS Property and the South West Arkansas Project, are located in southern Arkansas near the Louisiana state line. The company is focused on the evaluation and testing of commercial lithium extraction and purification from brine sourced from approximately 180,000 acres of unitized leases across these two projects. The company operates a first-of-a-kind industrial-scale Direct Lithium Extraction (“DLE”) Demonstration Plant at the LANXESS Property Project. The scalable, environmentally friendly process eliminates the use of evaporation ponds, reduces processing time from months to hours and greatly increases the effective recovery of lithium. A Definitive Feasibility Study (“DFS”) and Front-End Engineering Study (“FEED”) for Phase 1A of the LANXESS Property Project commenced in September 2022. A Preliminary Feasibility Study (“PFS”) of the South West Arkansas Project commenced in May 2022. The company is also pursuing the resource development of approximately 45,000 acres of mineral leases located in the Mojave Desert in San Bernardino County, California. Standard Lithium is jointly listed on the TSX Venture Exchange and the NYSE American under the trading symbol SLI and on the Frankfurt Stock Exchange under the symbol S5L. For more information, please visit the company’s website at www.StandardLithium.com.

NOTE TO INVESTORS: The latest news and updates relating to SLI are available in the company’s newsroom at https://ibn.fm/SLI

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

• SideChannel is a company focused on making cybersecurity simple and accessible based on the belief that all companies, including small and mid-sized businesses, deserve top-tier security guidance
• Currently, companies are facing the potential of stiffer economic times, demanding more cost-effective solutions to maintain and grow operations
• In these uncertain times, SideChannel offers a significant cost advantage as it provides top-tier security guidance at a manageable cost

In response to tighter budgets, companies have been focused on reducing expenses, streamlining operations, managing cash flows, and building cash reserves, among other interventions. At the same time, companies are recognizing the growing importance of cybersecurity. A November 2022 Global Tech Investment Predictions Report published by IBM and Morning Consult ranks cybersecurity solutions as the second top technology companies plan to invest in over the next two years, after 5G. The report further lists cyber risks as the leading factor driving investments in technology in organizations (https://ibn.fm/sMTnN). Furthermore, separate predictions expect the rising cybersecurity threats and risks to continue into 2023 and beyond (https://ibn.fm/nvHfO), crystallizing the decision by companies to pursue the above investments.

The need to control costs is forcing companies to prioritize less expensive services over costlier products (https://ibn.fm/P61Hn). Coupled with the growing demand for cybersecurity, companies are aggressively seeking the most cost-effective solutions to keep their operations safe. The situation works to the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.